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It has long been established in traditional forms of medicine and in anecdotal
knowledge that the health of the body and the mind are inextricably linked. Strong
and continually developing evidence now suggests a link between disorders which
involve Hypothalamic-Pituitary-Adrenal axis (HPA) dysregulation and the risk of developing
psychiatric disease. For instance, adverse or excessive responses to stressful experiences
are built into the diagnostic criteria for several psychiatric disorders, including depression
and anxiety disorders. Interestingly, peripheral disorders such as metabolic disorders and
cardiovascular diseases are also associated with HPA changes. Furthermore, many other
systemic disorders associated with a higher incidence of psychiatric disease involve a
significant inflammatory component. In fact, inflammatory and endocrine pathways seem
to interact in both the periphery and the central nervous system (CNS) to potentiate states
of psychiatric dysfunction. This review synthesizes clinical and animal data looking at
interactions between peripheral and central factors, developing an understanding at the
molecular and cellular level of how processes in the entire body can impact on mental
state and psychiatric health.
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disorders, inflammatory processes
INTRODUCTION
The concept that our mind and our mental processes are influ-
enced by the health of our bodies is intuitively appealing and
central to many approaches to health and wellbeing. However,
there has been a recent explosion of clinical and physiologi-
cal evidence to support this theory, shifting a “commonsense”
approach to health toward a clinically useful and pharmacolog-
ically targetable model. We are now moving toward mechanistic
models for the interactions between peripheral and central fac-
tors, gaining an understanding at the molecular and cellular level
of how processes in the entire body can impact on mental state
and psychiatric health. Although good evidence exists for these
associations in many psychiatric disorders, in this review we will
focus on depression, for which the evidence is perhaps most
compelling.
Some epidemiological associations between corporeal disor-
ders and psychological ill-health are well established. The link
between coronary artery disease and depression, for example, has
been extensively investigated (Nemeroff and Musselman, 2000;
Rugulies, 2002; Barth et al., 2004), and it appears that not only
are the two disorders strongly associated but that depression is
a predictor of poor cardiovascular outcome. Such epidemiologi-
cal evidence reinforces the widely held notion that the sadness of
depression both co-occurs with and potentiates cardiac disease.
However, we are now moving toward an understanding of the
shared molecular processes which may underpin the link between
these disorders.
Although evidence of psychiatric and peripheral comorbidities
abounds in the literature, there is also growing interest in the
more subtle variations in physiological function which may be
antecedents of overt illness but which may be sufficient to modu-
late CNS processes and mental state. In this review we will focus
on several of the major pathways implicated in the aetiology of
depression which may mediate the links between the mind and
body.
SYSTEMIC DISORDERS ASSOCIATED WITH DEPRESSION
Strikingly, a recent study conducted in the United States indicated
that of middle aged or older adults meeting diagnostic criteria
for a major depressive disorder, two thirds reported comorbid
cardiovascular disease (González and Tarraf, 2013). Up to 20%
of patients with coronary heart disease meet diagnostic crite-
ria for major depression, and up to 47% report significant and
long-lasting depressive symptoms (Bush et al., 2005; Carney
and Freedland, 2008). Recent reports have indicated that this
effect is not restricted to individuals with cardiovascular dis-
ease, as patients undergoing rehabilitation for pulmonary disease
were even more likely than cardiac patients to exhibit clini-
cally significant depression and psychological distress (Serber
et al., 2012). Cardiovascular risk factors are pathologically rele-
vant even prior to diagnosis. Studies of patients with long-term
depressive or anxiety disorders revealed elevated incidence of
sub-clinical cardiovascular disease, as measured by a variety of
parameters including plaque deposition and arterial stiffness
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(Seldenrijk et al., 2013), and blood pressure, glucose, body mass
index (BMI), diet, and physical activity (Kronish et al., 2012).
Interestingly, and relevant to sex differences often observed in
the context of anxiety and depressive disorders [for which preva-
lence can be as twice higher in women compared to men, see
Bekker and van Mens-Verhulst (2007); Kimbro et al. (2012)],
significant depressive symptoms are more common in younger
women with peripheral arterial disease than in other gender-age
groups (Smolderen et al., 2010). Also, recent meta-analysis of
cardiovascular risk factors and depression in later life demon-
strated relatively strong associations between depression and dia-
betes, cardiovascular disease and stroke (Valkanova and Ebmeier,
2013).
These findings also highlight the relationship between dia-
betes and psychiatric health. Meta-analytic evidence suggests that
patients with depression have an elevated risk of developing type
two diabetes (Knol et al., 2006; Mommersteeg et al., 2013), and
conversely that patients with diabetes have significantly increased
risk of developing depression (Anderson et al., 2001; Rotella and
Mannucci, 2013). A longitudinal study revealed that the inci-
dence of diabetes was highest in individuals with the greatest
number of depressive symptoms (Carnethon et al., 2003), and
a large community-based study demonstrated that diabetes was
associated with an increased risk of depression (de Jonge et al.,
2006). This bi-directional relationship is suggestive of convergent
pathological processes rather than a simplistic cause and effect
relationship. Interestingly, some clinical studies have hypothe-
sized that the doubled rates of depression in female diabetic
patients could help explain the high prevalence of coronary heart
disease in women with diabetes (Clouse et al., 2003).
Autoimmune disease, for example rheumatoid arthritis, is also
associated withmarkedly elevated risk of depression (Margaretten
et al., 2011a; Covic et al., 2012). Notably, there appears to be
a strong correlation between the severity of rheumatoid arthri-
tis and the incidence of depression, with a recent meta-analysis
demonstrating that those with the most severe form of arthritic
disease have a six-fold higher incidence of depression relative to
those with the mildest form Godha et al. (2010).
Clearly the impact of declining quality of life associated with
severe systemic disease cannot be overlooked. However, these
findings and the many others describing strong associations with
psychiatric disease and peripheral illness do provoke the question
of whether there are fundamental mechanisms in common. How
does the health of the body affect the health of the mind, and
what are the underlying pathological processes which underpin
this relationship? Although we do not yet have a full under-
standing of the complexities of the bidirectional relationship
between body and brain, convergent evidence suggests that the
endocrine response to stress (via the HPA axis), and immune
dysregulation (via inflammatory pathways), may be playing a
central role.
STRESS RESPONSIVITY AND THE
HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
The most well established example of mind-body interaction is
the link between psychological stress and psychological ill-health.
In fact, adverse or excessive responses to stressful experiences
are built into the diagnostic criteria for several psychiatric dis-
orders, including depression and anxiety disorders. The body’s
response to stress is mediated by the hypothalamic-pituitary-
adrenal (HPA) axis, by which stressful stimuli modulate the
activity of a tightly regulated cycle of circulating hormones. Stress
per se is not necessarily problematic; the body is well equipped to
respond to stressful stimuli and to some extent stress is necessary
for normal function. However, excessive or prolonged stress, or
perturbations in the function or regulation of the HPA axis may
result in abnormal changes in hormones circulating through both
the periphery and the CNS. As previously mentioned, women are
twice as likely as men to suffer from stress-related psychiatric dis-
orders and there is evidence that sex differences in stress responses
could account for this sex bias (Bangasser and Valentino, 2012).
The HPA axis is the primary circuit that mediates the phys-
iological response to stress and regulates the level of circulat-
ing glucocorticoid hormones (e.g., CORT: cortisol in humans,
corticosterone in rodents). Arginine vasopressin (AVP) and
corticotrophin-releasing hormone (CRH, also originally referred
to as CRF for corticotrophin-releasing factor) are synthesised
and released from the paraventricular nucleus (PVN) of the
hypothalamus, and are arguably the highest order regulators of
the HPA axis activity within the central nervous system (CNS).
These neuro-hormones act synergistically to stimulate adreno-
corticotrophin (ACTH) secretion from the anterior pituitary,
culminating in increased levels of circulating CORT. The HPA
axis is modulated by a negative feedback loop encompassing the
hippocampus, hypothalamus and anterior pituitary. Following
CORT secretion into the peripheral blood circulation, CORT
passes through the plasma membrane of cells, particularly in the
pituitary, hypothalamus, and hippocampus where it binds to the
glucocorticoid receptor (GR). Finally, glucocorticoid catabolism
involves 5α-reductase type 1 (predominantly a liver enzyme) and
11β-hydroxysteroid dehydrogenase type 2 (in kidney).
The psychological determinants of an individual’s response
to stress are important predictors of outcome, although this
area is beyond the scope of this review [reviewed comprehen-
sively by Liu and Alloy (2010)]. However, physiological variations
in HPA axis function and related pathways may also modu-
late the response to stress and alter the threshold for psychiatric
disorders. Despite substantial limitations in the objective assess-
ment of stress, multiple studies have documented an association
between stressful life experiences and depression (Kendler and
Gardner, 2010). Interesting examples of HPA axis dysfunction
modulating psychiatric health come from Cushing’s syndrome
and Addison’s disease, states of hyper- and hypo-cortisolemia,
respectively. Cushing’s syndrome is associated with a high preva-
lence of psychopathology, primarily depressive symptoms but
also mania and anxiety (Pereira et al., 2010). Addison’s disease has
been less extensively investigated but appears to be associated with
an increased risk of a variety of psychiatric symptoms, including
depression, delusions, hallucinations, and anxiety (Anglin et al.,
2006). In both disorders it should be borne in mind that adrenal
dysfunction can also lead to electrolyte and metabolic abnormal-
ities which can also contribute to CNS disturbances. Nonetheless,
the fact that treatment of the hyper- or hypo-cortisolaemia
resolves the psychiatric symptoms in most cases strongly suggests
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that changes in adrenal corticosteroids are a primary driving force
for the psychiatric symptoms (even though this is not the sole
determining factor, as half of subjects with Cushing’s do not
develop depressive symptoms). Therapeutic administration of
high doses of corticosteroids has been associated with the devel-
opment of a manic behavioral state (Warrington and Bostwick,
2006; Kenna et al., 2011; Fardet et al., 2012). These observations
also highlight a critical pathway by which HPA axis function may
altermental state. Corticosteroids are generally prescribed in cases
of uncontrolled inflammatory disease, and act as powerful anti-
inflammatory factors. As we will discuss below, inflammatory
states are strongly linked to perturbations in psychiatric health.
More subtle variations in HPA axis function have been directly
associated with psychiatric disorders, in particular depression. A
recent meta-analysis described the magnitude of the difference
between depressed and non-depressed group in cortisol, ACTH
and CRH levels. Looking at 361 studies, the results show that
overall depression is associated with small-to-moderate elevations
in ACTH and cortisol and a reduction in CRH levels (Stetler and
Miller, 2011). However, in older people, the association between
cortisol and major depression was U-shaped (Bremmer et al.,
2007). Another large cohort study revealed significant associa-
tions between major depressive disorders and specific HPA axis
indicators, such as a higher cortisol awakening response in MDD
patients compared to controls (Vreeburg et al., 2009). Those
modest but significant differences were also observed in patients
with anxiety disorders (Vreeburg et al., 2010).
In line with clinical findings, the circadian pattern of corti-
costerone has been reported to be disrupted in rodent models of
depression (Touma et al., 2009; Bonilla-Jaime et al., 2010). In rats,
chronic stress induces a depressive-like phenotype, associated
with dysregulation of the HPA axis and reductions in dopaminer-
gic and serotonergic transmissions in the PFC (Mizoguchi et al.,
2008). Affective-like behavioral deficits have been reported in
mouse mutants with altered HPA axis function [see Renoir et al.
(2013) for review]. Chronic treatment with corticosterone as well
as isolation rearing increase the depressive-like behavior in GR-
dependent and independent manners (Ago et al., 2008). Chronic
elevation of corticosterone creates a vulnerability to a depression-
like syndrome that is associated with increased expression of
the serotonin synthetic enzyme tryptophan hydroxylase 2 (tph2),
similar to that observed in depressed patients (Donner et al.,
2012). Interestingly, the effects of chronic corticosterone admin-
istration in animal models have also been studied in the context
of affective and systemic disorders. In that regard, chronic cor-
ticosterone in mice was found to induce anxiety/depression-like
behaviors (David et al., 2009) as well as decrease sucrose con-
sumption in a model of anhedonia (Gourley et al., 2008). Chronic
antidepressant treatment reversed those behavioral impairments.
Furthermore, relevant to the relationship between stress and
metabolic syndrome, 4-wk exposure to high doses of corticos-
terone in mice, has been found to increase weight gain and
plasma insulin levels as well as reduce home-cage locomotion
(Karatsoreos et al., 2010).
Using a chronic mild stress (CMS) paradigm, in which
mice were housed individually and alternatively submitted to
unpredictable “mild” stressors (such as periods of continuous
overnight illumination, short periods of food/water deprivation
etc.), Palumbo et al. (2010) found that mice subjected to the CMS
procedure exhibited an increase in serum corticosterone levels
during the first few weeks of exposure. However, these elevated
corticosterone levels returned to baseline levels after 6 weeks of
CMS. Similarly, Adzic et al. (2009) reported reduced CORT lev-
els in chronically isolated rats (for 21 days), whereas CORT was
increased after an acute 30-min immobilization stress. Altered cir-
cadian activity of the HPA axis has also been reported in a CMS
rat model of depression (Christiansen et al., 2012). Interestingly,
this study suggests a recovery of diurnal corticosterone rhythm
after 8 weeks of CMS. Taken together, these observations sug-
gest an adaptive capacity for the HPA axis to cope with prolonged
stress.
The effects of chronic stress on HPA axis function have
been widely studied in both animal models and clinical popu-
lations. Many of those investigations have focused on the neg-
ative feedback part of the HPA axis (mainly mediated by the
GR). Such feedback is efficiently probed by the established com-
bined dexamethasone-suppression/corticotrophin-releasing hor-
mone stimulation (dex/CRH) test (Ising et al., 2007). Altered
dex/CRH test are seen in major depression (Mokhtari et al.,
2013) as well as in chronic stress conditions. For example, over-
commitment in chronically work-stressed teachers was signifi-
cantly associated with blunted response to the dex/CRH challenge
(Wolfram et al., 2013). Further regression analyses showed that
low social support at work and high job strain were associated
with more cortisol suppression after the dexamethasone sup-
pression test (Holleman et al., 2012). In rodents, social isolation
decreased the feedback sensitivity of the HPA axis to dexametha-
sone (Evans et al., 2012). Another animal study reported that
socially deprived mice had increased adrenal weights as well as a
greater increase in corticosterone levels in response to acute stress
(Berry et al., 2012). Interestingly, those chronic stress-induced
HPA axis dysfunctions were associated with depressive/anxiety-
like behavior as well as impaired hippocampal plasticity (i.e.,
altered hippocampal neurogenesis and reduction in BDNF levels)
(Berry et al., 2012; Evans et al., 2012).
Polymorphisms in genes controlling the activity of the HPA
axis are also associated with differential risk of psychiatric disease.
Polymorphisms in the GR gene have been associated with major
depression in multiple cohorts (vanWest et al., 2005; van Rossum
et al., 2006) [but also see Zou et al. (2010); Zimmermann et al.
(2011)]. Interestingly, some GR polymorphisms are also a predic-
tor of the HPA axis response to psychosocial tests (Kumsta et al.,
2007) and have been found to be associated with the extent of
stress hormone dysregulation in major depression (Menke et al.,
2013). Genotype-phenotype associations have also been identi-
fied in terms of response to antidepressant response (Ellsworth
et al., 2013). Evidence of gene-environment interactions in the
stress response and psychiatric susceptibility comes from a study
of the corticotrophin-releasing factor receptor (CRF-R) (Bradley
et al., 2008). Individuals with a particular CRF-R genotype who
had experienced child abuse had enhanced risk of depression as
adults, an observation repeated in two ethnically different pop-
ulations. Overall, studies suggest that the degree of HPA axis
hyperactivity can vary considerably across psychiatric patient
www.frontiersin.org December 2013 | Volume 4 | Article 158 | 3
Renoir et al. Mind-body interactions and psychiatric diseases
groups, likely due to genetic and environmental factors during
early development or adult life. In that regard, two separate
studies reported that polymorphisms of the FKBP5 gene that
potentially modify the sensitivity of the GR are associated with an
increased likelihood of adult depression for individuals exposed
to adverse life events (Zimmermann et al., 2011) and child-
hood physical abuse (Appel et al., 2011). Genes involved in other
pathways may also potentiate an aversive response to stress. A
landmark early study described an association between a variant
in the serotonin transporter gene and the response to stressful
life experiences (Caspi et al., 2003). This functional variant in
a major target of antidepressant therapies is associated with an
elevated response to fearful stimuli, elevated hormonal responses
to stress, and increased risk of depression in response to stress
exposure (Lesch et al., 1996; Hariri et al., 2002; Jabbi et al., 2007).
Variants in multiple genes in the serotonergic pathway have also
been associated with altered behavioral phenotypes in animal
models [reviewed in Holmes (2008)]. Critically, changes in circu-
lating corticosteroids can regulate the activity of the rate-limiting
serotonin synthetic enzyme tryptophan hydroxylase 2 in the brain
(Clark et al., 2005, 2007). In rodent models, acute restraint stress
up-regulates serotonin production in the amygdala (Mo et al.,
2008), whilst chronic administration of ACTH to disrupt HPA
axis function results in an increased level of serotonin in the pre-
frontal cortex in response to acute stress (Walker et al., 2013).
Taken together these findings demonstrate that alterations inHPA
axis function can directly impact on CNS systems known to be
associated with psychiatric disease.
PERIPHERAL DISORDERS ASSOCIATEDWITH HPA CHANGES
AND PSYCHIATRIC DISEASE
A wealth of evidence is now emerging to illustrate the link
between stress and risk factors for physiological disorders, in
particular metabolic disorders. Hyperactivity of the HPA axis
and hypercortisolaemia is associated with the metabolic syn-
drome (Anagnostis et al., 2009). Similarly, both chronic stress and
chronic treatment with glucocorticoids are associated with central
adiposity, dyslipidaemia, atrophy of skeletal muscles, insulin resis-
tance, and glucose intolerance: a suite of symptoms remarkably
resemblant of the metabolic syndrome itself (Kyrou and Tsigos,
2009; van Raalte et al., 2009).
Elevations of circulating glucocorticoids have also been linked
with an increased risk of depression in those with metabolic dis-
order (Vogelzangs et al., 2009), and relative insensitivity to the
dexamethasone suppression test has been documented in patients
with this disorder (Kazakou et al., 2012). On the other hand, dis-
turbances in fatty acid metabolism have been observed in cohort
studies of depression (Assies et al., 2010). Fatty acid levels appear
to have a bidirectional relationship with HPA axis activity, with
glucocorticoids modulating fatty acid metabolism (Brenner et al.,
2001;Macfarlane et al., 2008), and supplementation of polyunsat-
urated fatty acids reducing cortisol levels in both healthy subjects
(Delarue et al., 2003) and in those with depression (Jazayeri et al.,
2010; Mocking et al., 2012). A study examining this relationship
in more detail has shown that the circadian changes in cortisol
have a different association with the major fatty acid forms in
major depression patients compared to controls (Mocking et al.,
2013). Other studies have demonstrated both changes in vis-
ceral fat levels and adrenal gland volume in women with major
depressive disorders (Ludescher et al., 2008). Some of these asso-
ciations appear to have developmental antecedents, with exposure
to dietary high fat in the perinatal period being linked with both
altered HPA axis function and mood changes (Sasaki et al., 2013).
If metabolic disorders are considered as a spectrum, then dia-
betes is arguably positioned as the end point of this decline
in function. Chronic stress and sustained dysregulation of cor-
ticosteroid production are strongly associated with the devel-
opment of type 2 diabetes mellitus in both human cohorts
and in animal models (Chan et al., 2003; Rosmond, 2005;
Reagan et al., 2008; Anagnostis et al., 2009; Matthews and
Hanley, 2011). As an example in mice, streptozotocin (STZ)-
induced diabetes resulted in increased depressive-like behav-
ior as well as increased corticosterone levels (Ho et al., 2012).
The convergence of the associations between HPA axis dysfunc-
tion and both diabetes and depression is striking, with com-
pelling evidence for links between the two disorders and this
central underlying risk factor [reviewed in Champaneri et al.
(2010)].
Dysfunction of HPA signaling also appears to interact with
the autonomic nervous system to influence cardiovascular func-
tion. Components of the HPA axis act outside the hypothalamus
to regulate sympathetic outflow, and thus heart rate. Elevated
heart rate has been associated with depression in multiple stud-
ies (Forbes and Chaney, 1980; Carney et al., 1993, 2000; Lechin
et al., 1995), and is a strong predictor of multiple parameters of
cardiovascular disease, including myocardial ischaemia, arrhyth-
mias, hypertension, and cardiac failure (Dyer et al., 1980; Kannel
et al., 1987; Palatini and Julius, 1997). Depression is associated
with an increased risk of mortality in patients with cardiovascu-
lar disease (Mann and Thakore, 1999), and this increased risk is
strongly linked with hypercortisolaemia (Jokinen andNordstrom,
2009). In healthy subjects, cortisol and ACTH response to the
Dex/CRH test were negatively associated with central adiposity
and blood pressure and positively associated with HDL choles-
terol, strong risk factors for cardiovascular disease (Tyrka et al.,
2012).
Taken together, these studies speak to the accumulating evi-
dence suggesting a link between disorders which involve HPA
dysregulation and the risk of developing psychiatric disease. This
is illustrative of the bidirectional relationship between periph-
eral illness and mental health: HPA axis changes may be either
contributors to or consequences of peripheral disorders but also
have the capacity to modulate brain function and predispose to
psychiatric disease.
PHARMACOLOGICAL TARGETING OF THE HPA AXIS
The GR antagonist mifepristone has been tested as an adjunc-
tive treatment for psychiatric disorders (Schatzberg and Lindley,
2008). Most recently, a randomized controlled trial of adjunc-
tive mifepristone in patients with bipolar disorder demonstrated
alterations in cortisol levels which were correlated with improve-
ments on neuropsychological tests of working memory (Watson
et al., 2012). An earlier, smaller scale trial by the same group
showed improvements in both neurocognitive function and
Frontiers in Pharmacology | Neuropharmacology December 2013 | Volume 4 | Article 158 | 4
Renoir et al. Mind-body interactions and psychiatric diseases
depression rating scores (Young et al., 2004). However, a simi-
lar study in schizophrenia showed alterations in plasma cortisol
but no significant change in symptoms (Gallagher et al., 2005).
These mixed findings do highlight the potential utility of thera-
peutics targeting HPA axis function, but also are suggestive of the
heterogeneity in the role of the HPA axis across, and potentially
also within, psychiatric disorder diagnoses. The main challenge
in pharmacological targeting of the HPA axis is that blockage of
all GR-dependent processes could ultimately lead to counteractive
effects such as elevated endogenous corticosterone levels. In that
context, a newly developed high-affinity GR ligand (C108297)
shows promising characteristics in rats (Zalachoras et al., 2013).
Indeed, C108297 displays partial agonistic activity for suppression
of CRH gene expression and potently enhances GR-dependent
memory consolidation. This compound, which does not lead to
disinhibition of the HPA axis, could help in dissecting the molec-
ular signaling pathways underlying stress-related disorders. In
recent years, other therapeutic strategies interacting at different
levels of the HPA axis have been developed. Those include agents
acting on CRH-R1 receptor and adrenal steroidogenesis as well as
modulators of the 11β-hydroxysteroid dehydrogenase type (11β-
HSD1), the enzyme regulating cortisol metabolism (Thomson
and Craighead, 2008; Martocchia et al., 2011).
In patients who were successfully treated with fluoxetine,
the secretion of cortisol decreased (Piwowarska et al., 2012).
Furthermore, recent data suggest that GR levels in lymphocytes
could be used to predict response to antidepressant treatment
in major depressive patients (Rojas et al., 2011). However, it
should be noted that GR levels seemed inconsistent over time in
this study. Also, measuring cortisol levels in depressed patients
before and following treatment with SSRI, Keating et al. (2013)
concluded that that stress physiology was unlikely to be a key
factor in the response to antidepressant treatment. The varia-
tion in findings from these studies may reflect differing modes
of activity of the different antidepressant drug classes, superim-
posed on a heterogeneous patient population. This was illustrated
in a study examining changes in daily cortisol patterns in patients
using SSRIs, tricyclic antidepressants, other therapeutics or no
medications (Manthey et al., 2011). A complex pattern emerged,
with some antidepressants suppressing the morning peak in cor-
tisol, and others altering the response to the dexamethasone
suppression test. However, the challenges inherent to measuring
a circulating factor which is both diurnally regulated and acutely
sensitive to environmental cues should not be underestimated.
IMMUNE DYSREGULATION, INFLAMMATION AND
PSYCHIATRIC HEALTH
There is strong evidence that peripheral growth factors,
pro-inflammatory cytokines, endocrine factors, and metabolic
markers contribute to the pathophysiology of major depressive
disorders and antidepressant response (Schmidt et al., 2011).
Similarly, many of the systemic disorders associated with a higher
incidence of psychiatric disease involve a significant inflamma-
tory component. In fact, as our understanding of the aetiol-
ogy of these disorders deepens, it has become apparent that
there is significant overlap between the factors driving periph-
eral inflammatory disease and psychiatric disorders. Elevations
of pro-inflammatory cytokines have been observed in both clini-
cal populations and animal models of heart failure (Levine et al.,
1990; Francis et al., 2003), after coronary surgery (Hennein et al.,
1994), and following heart transplants (Azzawi and Hasleton,
1999). Importantly, the pathogenesis of atherosclerosis is intrin-
sically inflammatory (Koenig, 2001), with elevated local and
circulating pro-inflammatory cytokines. In addition, the acute-
phase marker C-reactive protein (CRP) is strongly associated with
cardiovascular disease (van Holten et al., 2013), and can be used
as a diagnostic or prognostic factor. As discussed above, cardio-
vascular disease is strongly associated with changes in psychiatric
health, in particular depression.
Cardiovascular disease is in turn closely linked with obe-
sity, dyslipidemia, diabetes and metabolic disease. The elevated
frequency of anxiety and depression in these disorders may in
part underlie the association between cardiovascular and psy-
chiatric risk factors. In studies of diabetic patient cohorts, the
inflammatory marker CRP was consistently predictive of direct
associations between depression severity, lipid profiles and obe-
sity levels (van Reedt Dortland et al., 2013). Similarly, increased
risk of depression in a cohort of patients with diabetes was asso-
ciated with a higher BMI, illustrating the link between depression
and poor control of cardiovascular risk factors (Kimbro et al.,
2012). Obesity itself is considered to be a state of low-grade
inflammation, and is linked with elevated depressive symptoms.
In addition, in a longitudinal study CRP levels at baseline were
statistically associated with depression scores (Daly, 2013).
Other disease states involving inflammatory processes are
associated with elevated risk of depression. Major depression is
the most common psychiatric manifestation of multiple sclero-
sis, with an incidence approaching 50% (Lo Fermo et al., 2010).
Likewise, although the incidence rate varies significantly between
studies, an elevated incidence of depression has been docu-
mented in systemic lupus erythematosus (Palagini et al., 2013)
and rheumatoid arthritis (Dickens et al., 2002). Common to all of
these disorders is an autoimmune-mediated elevation of inflam-
matory signaling, with increased circulating pro-inflammatory
cytokines observed in the periphery and in the CNS. Large case-
control studies have described increased rates of anxiety and
depression in patients with inflammatory bowel disease (Kurina
et al., 2001; Ananthakrishnan et al., 2013a,b). Altered gut perme-
ability to enteric bacteria has also been associated with depression.
Translocation of bacterial allergens [in particular lipopolysac-
charide (LPS)], stimulates a systemic immune response char-
acterized by elevated IgM and IgA antibodies reactive to the
bacteria. Individuals with chronic depression are more likely to
display increased LPS-reactive IgM and IgA than control subjects,
indicating that elevated gut permeability may be potentiating a
systemic inflammatory state (Maes et al., 2008, 2012a).
The case for altered peripheral inflammation in psychi-
atric disease is strong, perhaps most so for major depression.
Individuals with clinically classifiable major depression exhibit a
wide range of changes in inflammatory markers, including ele-
vated cytokines, chemokines, and acute phase proteins, findings
which have been replicated in several meta-analyses and which
in some studies appear to be correlated with specific depressive
symptoms (Miller et al., 2009). There appears to be a shift in the
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function of the immune system in depression, with an increase
in pro-inflammatory cytokines accompanied by a decrease in
cellular immunity (Zorrilla et al., 2001; Dowlati et al., 2010).
The strength of these findings is heightened by a positive corre-
lation between the elevations in pro-inflammatory cytokines and
the severity of depression rating scores (Howren et al., 2009). A
recent longitudinal population-based study demonstrated strong
associations between depressive symptoms and elevated levels of
the pro-inflammatory cytokine IL-6 and CRP (Lu et al., 2013).
Notably, heightened IL-6, CRP and depressive symptoms were
all predictive of reduced pulmonary function, in a cohort with
no known history of obstructive pulmonary disease. This large
study highlights the substantial cross-over between inflammatory
disease and depressive symptomatology. However, there may be
differences between sub-populations in depression, with some
individuals more likely to display an inflammatory pathophys-
iology. Although the number of patients classified as suffering
atypical depression is relatively low, these patients may be more
likely to show high levels of inflammatory markers such as CRP
(Hickman et al., 2013). Part of the population variance may
result from polymorphisms in the CRP gene. The association
between CRP levels and depressive symptoms may be moderated
by CRP gene haplotype, in a complex manner which may under-
pin some of the variations in other association studies (Halder
et al., 2010). Patients receiving therapeutic administration of
cytokines for cancer or chronic viral infections, [in particular
interferon (IFN)-alpha and interleukin-2] frequently experience
psychiatric symptoms, including the development of frank major
depression in a significant proportion of patients (Capuron et al.,
2004; Raison et al., 2005). IFN-alpha stimulates both peripheral
and central release of pro-inflammatory cytokines, a fact which
underpins the behavioral effects of this cytokine and highlights
the capacity for systemic immune signals to regulate CNS pro-
cesses (Capuron et al., 2000, 2001, 2002, 2003, 2004; Raison et al.,
2005; Eller et al., 2009; Alavi et al., 2012; Birerdinc et al., 2012;
Udina et al., 2012).
Of particular relevance to the treatment of depressive disorders
is the emerging evidence that at least part of the therapeutic effi-
cacy of currently available antidepressants may result from their
concomitant anti-inflammatory effects. Although the response
rate and efficacy of current antidepressants is far from universal,
at least some patient populations derive significant benefit from
these medications. However, the previously accepted notion that
modulation of synaptic monoamines represents the sum total of
the therapeutic effects of these drugs has now come into ques-
tion. Recent studies have shown that selective-serotonin-reuptake
inhibitor medications can suppress immune cell activation and
release of inflammatory cytokines in the periphery and ex-vivo
(Diamond et al., 2006; Taler et al., 2007; Branco-de-Almeida et al.,
2011). Notably, this immune-regulatory effect is not restricted
only to the periphery, but can also affect microglia, the immune
cells of the CNS (Hashioka et al., 2007; Horikawa et al., 2010).
A recent meta-analysis of human depression studies showed that
antidepressant treatment at least partially ameliorates the eleva-
tions of pro-inflammatory cytokines associated with the disorder
(Hannestad et al., 2011). Although it is clear that drug discov-
ery in psychiatric disease needs to look beyond established drug
classes, these findings emphasize the potential clinical utility of
targeting inflammatory function in depression. Finally, potential
sex-differences have been suggested when assessing the effects of
LPS on cytokine gene expression. Indeed, females had increased
hippocampal levels of IL-6 of TNF-α with respect to males after
repeated administration of LPS (Tonelli et al., 2008).
MECHANISMS OF IMMUNE MODULATION OF PSYCHIATRIC
FUNCTION
Historically the CNS was regarded as a “privileged” site with
regards to the immune system, with little immune communi-
cation across the blood-brain barrier except in cases of frank
CNS infection. However, it is now clear that the brain is sensitive
to peripheral immune stimuli and can respond with activation
of central immune cells and local production of inflammatory
cytokines. Microglia are the CNS equivalent of macrophages,
releasing cytokines upon activation and facilitating a central
immune response, even in the absence of peripheral immune
cell migration into the CNS. The brain’s response to peripheral
inflammatory stimuli can be seen most clearly in the pattern of
behavioral changes which reliably results from systemic infec-
tion, administration of synthetic bacterial wall components or
administration of cytokines (Dantzer, 2004; Pucak and Kaplin,
2005). Termed “sickness behavior,” this encompasses changes in
motor activity, consummatory behavior, social interaction, circa-
dian rhythms, and responsivity to hedonic and aversive stimuli.
The parallels between these behavioral changes and aspects of
depression have been well noted and have been a prompt for
extensive research.
Systemic administration of synthetic bacterial endotoxin, or
LPS, induces a well-established pattern of peripheral inflam-
mation. However, multiple studies have now also demonstrated
that systemic inflammation activates CNS microglia, including in
non-human primates (Henry et al., 2008; Hannestad et al., 2012).
In mice, systemic LPS causes microglial activation and synthesis
of cytokines (Puntener et al., 2012). Microglia form close contacts
with synaptic structures and appear to regulate synaptic strength
(Wake et al., 2009). These cells also express multiple neurotrans-
mitter receptors and are therefore acutely responsive to neuronal
signaling (Kettenmann et al., 2011). Activated microglia are also
a key source of reactive oxygen species, contributing to a status
of inflammation-induced oxidative stress in the CNS (Dringen,
2005). Oxidative stress, driven both peripherally and centrally, is
strongly associated with psychiatric aetiology.
Reduced plasma L-tryptophan, the precursor for serotonin, is
a potential biomarker of “vulnerability to depression” (Maes et al.,
1993). Indeed, tryptophan depletion is widely used to study the
contribution of reduced serotonin transmission to the pathogen-
esis of major depressive disorder (Van der Does, 2001) and also
relevant in the context of immune activation (Kurz et al., 2011).
The depressive symptomatology associated with immunomodu-
latory therapy may be mediated in part by changes in tryptophan
metabolism. Pro-inflammatory cytokines such as IFN-γ, IFN-α,
and TNF-α, and reactive oxygen species, induce activation of the
enzyme, indolamine 2, 3 dioxygenase (IDO) in microglia, which
metabolizes tryptophan via the kyneurenine pathway (Maes,
1999; Wichers et al., 2005; Dantzer et al., 2008; Maes et al.,
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2012b). This shifts the balance of tryptophan toward kynure-
nine and away from serotonin, reducing serotonin bioavailability
(Capuron et al., 2002, 2003; Vignau et al., 2009). Notably, in
the CNS only microglia further metabolize kynurenine to quino-
linic acid, which exerts neurotoxic effects (Guillemin et al., 2005;
Soczynska et al., 2012). Patients treated with IFN-α for hepati-
tis C infection developed depressive symptoms including negative
moods that were correlated with increased levels of kynurenine
(Wichers et al., 2005). In addition, analysis of plasma tryp-
tophan and kynurenine pathway metabolites in patients with
major depression showed increased rates of tryptophan degrada-
tion compared to normal control subjects (Myint et al., 2007).
Taken together, these findings indicate that cytokine-induced
microglial activation can mediate changes in neurotransmitters
and other bioactive metabolites which may underpin mood dis-
orders. Also, recent data indicate that cognitive impairments (as
well as the decline in neurogenesis observed during ageing) can
be in part attributed to dysregulation in blood-borne factors such
as changes in peripheral CCL11 chemokine levels (Villeda et al.,
2011). These findings support the crosstalk between peripheral
molecular processes to central effects related to cognitive and
emotional function.
PHARMACOLOGICAL TARGETING OF INFLAMMATORY
PATHWAYS
Several of the therapies for the inflammatory disorder rheuma-
toid arthritis potentiate the effects of antidepressant therapies
(Margaretten et al., 2011b). Such drugs target pro-inflammatory
cytokine pathways, for example TNF-α antagonists such as etan-
ercept. This particular drug is also commonly used in the
treatment of the inflammatory skin condition psoriasis, and
large-scale studies of this drug have indicated that patients with
psoriasis receiving this drug show reduced depression scores rel-
ative to placebo (although the level of depressive symptoms in
these patients was relatively low overall, and would not con-
stitute a diagnosis of major depression) (Tyring et al., 2006).
Interestingly, follow-up studies indicated that the change in
depression score was independent of disease state (Krishnan
et al., 2007). Drugs with a similar TNF-α antagonist activity
have also shown antidepressant activity in trials in patients with
other inflammatory conditions, including Crohn’s disease and
ankylosing spondylitis (Persoons et al., 2005; Ertenli et al., 2012).
Critically, a recent study of the TNF-α antagonist infliximab in
otherwise healthy patients with major depression demonstrated
that the antidepressant activity of this drug was dependent on the
level of inflammatory markers at baseline (Raison et al., 2013).
This study demonstrated that depressed patients with higher
levels of the inflammatory markers TNF-α and CRP showed
a decrease in depression rating scores over the course of the
study. It is also worth noting that the patients in this study were
poorly responsive to classical antidepressant therapy, which may
indicate that a sub-population exists in whom inflammation is
correlated with both poor antidepressant response and efficacy
of anti-inflammatory medication. A second recent study also
demonstrated that patients with depression who experienced a
decline in symptoms with infliximab treatment also showed ele-
vated inflammatory gene expression in peripheral immune cells
(Mehta et al., 2013). Response to infliximab was also associated
with reductions in the expression of other genes involved with
innate immune activation. Agents such as infliximab are too large
to cross the blood-brain barrier, and therefore the amelioration
of depressive symptoms is more likely associated with resolution
of peripheral inflammation than direct effects of the drug in the
brain. However, as we have discussed above, CNS microglia are
acutely sensitive to circulating cytokine levels and so their level of
activity may well be modulated by anti-inflammatory treatment.
The developing focus on inflammatory function in depression
has spurred trials of other anti-inflammatory drugs as adjuncts to
antidepressant treatment. A large-scale longitudinal population
study revealed that statin users were less likely than non-users
to have depression at baseline (Otte et al., 2012). Statin users
who did not have depressive symptoms at baseline were also
less likely to develop depression during the follow-up period.
Statins are commonly prescribed to individuals who have had a
cardiac event or intervention. A prospective study in this popula-
tion showed that prescription of statins reduced the likelihood of
developing depression by up to 79% (Stafford and Berk, 2011).
A large community study also documented reduced exposure
to statins and aspirin (another non-steroidal anti-inflammatory
agent) in women with major depressive disorder (Pasco et al.,
2010). Likewise, women who were exposed to these agents were
also less likely to develop depression over the course of the study.
Similar results were also observed in a large population-based
cohort of elderly patients, with statins exerting a protective effect
against the development of depressive symptoms (Feng et al.,
2008). Notably, this study also documented a positive correlation
between the use of systemic corticosteroids and depression.
The cyclooxygenase-2 (COX-2) inhibitor celecoxib is a non-
steroidal anti-inflammatory drug used widely in the treatment
of pain, particularly related to arthritic conditions. This drug
has been found to improve depressive symptoms when adminis-
tered in conjunction with the antidepressants sertraline (Abbasi
et al., 2012), reboxetine (Muller et al., 2006), and fluoxetine
(Akhondzadeh et al., 2009). However, it should be noted that
other trials have resulted in conflicting findings, with several
showing no beneficial effect of celecoxib in depression (Musil
et al., 2011; Fields et al., 2012). The discrepancies in these
study results are potentially reflective of the complexity of the
inflammatory pathways, in which COX-2 and many other key
molecules may play multiple roles. In the brain, COX-2 has
anti-inflammatory and neuroprotective effects (Minghetti, 2004),
and COX-2 deficient mice show increased neuronal damage,
microglial reactivity and oxidative stress markers (Aid et al.,
2008). Hence targeting of inflammatory pathways in depres-
sion requires careful investigation of both peripheral and cen-
tral responsivity. COX-2, in particular, may not be the most
appropriate target for adjunct therapies in depression [reviewed
in Maes (2012)]. In addition, modulation of immune and
inflammatory signaling necessitates caution with regard to the
potential of lowering defenses to opportunistic infection and
malignancy. Long term use of immune-modifying drugs has
been associated with increased incidence of serious infections
and cancer (Bongartz et al., 2006; Atzeni et al., 2012; van
Dartel et al., 2013). This raises the possibility that agents which
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directly regulate the CNS rather than peripheral inflamma-
tory response, or have more mild anti-inflammatory effects,
may be more appropriate targets for the pharmacotherapy of
depression.
Still peripherally-active, but arguably milder in effect, are the
non-steroidal anti inflammatory medications, including aspirin.
Animal studies using aspirin have shown moderate but dis-
cernible effects on depressive behavior (Brunello et al., 2006;
Wang et al., 2011). Preliminary clinical trials have correlated this,
showing a synergistic effect of co-therapy with antidepressants
and aspirin (Mendlewicz et al., 2006). However, perhaps more
compelling is the result from a large-scale longitudinal cohort
study, which documented an association between aspirin use and
lowered risk of depression (Pasco et al., 2010). Echoing this is
a cross-sectional study which demonstrated that men with ele-
vated plasma homocysteine, a marker of cardiovascular risk, had
a reduced risk of depression if they had been taking aspirin
(Almeida et al., 2012).
Minocycline, a second-generation tetracycline derivative, has
recently attracted significant attention for its potential efficacy as
an antidepressant. This well characterized drug has potent anti-
inflammatory and neuroprotective effects which are independent
of its antibiotic efficacy (Pae et al., 2008; Dean et al., 2012).
Most importantly, minocycline readily crosses the blood brain
barrier and is known to inhibit microglial activation (Pae et al.,
2008; Dean et al., 2012). Studies in mice have demonstrated that
minocycline attenuated the elevations in CNS IL-1β, IL-6, and
IDO induced by bacterial endotoxins (Henry et al., 2008). This
study also showed that pre-treatment with minocycline prevented
the development of depressive-like behavioral endophenotypes,
and normalized the kynurenine/tryptophan ratio in the plasma
and brain (Henry et al., 2008). These findings clearly indicate
that minocycline has effects on microglia through inhibition
of the synthesis of pro-inflammatory cytokines and IDO up-
regulation, and that these may flow through to ameliorate mood
states. Echoing this, a small open-label study reported minocy-
cline (150mg/kg/day) in combination with serotonin reuptake
inhibitor contributed to ameliorate depressive mood and psy-
chotic symptoms in patients with psychotic unipolar depression
(Miyaoka et al., 2012).
The developing appreciation of the role of inflammatory func-
tion in depression has highlighted the potential role of dietary
sources of anti-inflammatory species. Deficiencies of the anti-
oxidant and anti-inflammatory Coenzyme Q10 (CoQ10) have
been associated with depressed mood (Maes et al., 2009), and
a preliminary study of supplementation with CoQ10 showed an
amelioration of depression scores in a cohort with bipolar disor-
der (Forester et al., 2012). Several studies in pre-clinical models
have shown potential antidepressant effects of omega 3 fatty acids
(Watanabe et al., 2004), and conversely, deficient diets during pre-
natal development have been associated with persistent changes
in mood state (Chen and Su, 2013). Compounding this, altered
lipid profiles have been described in the cortex of patients with
mood disorders (Tatebayashi et al., 2012). Large-scale popula-
tion assays have shown associations between dietary lipid profiles
and the risk of depression (Hoffmire et al., 2012). Although the
outcomes of clinical trials using omega 3 supplementation are
still under some debate, recent meta-analyses have pointed to
some degree of improved outcome in depressed patients (Lin
and Su, 2007; Bloch and Hannestad, 2012; Martins et al., 2012).
Intriguingly, omega 3 fatty acids have received particular atten-
tion for the treatment of depressive symptoms post-myocardial
infarction (Gilbert et al., 2013; Siddiqui and Harvey, 2013). In
such cases, the anti-inflammatory effects of this lipid may be
ameliorating both the peripheral inflammatory state and the
secondary central inflammation.
INTERFACES BETWEEN HPA AXIS AND IMMUNE
DYSFUNCTION
Whilst it is clear that both inflammation and HPA dysfunc-
tion are associated with psychiatric pathology, these two systems
interact at multiple levels and may together constitute a syn-
ergistic effect on neuronal function. Across the spectrum of
systemic disorders associated with peripheral inflammation and
an increased risk of depression, many are also associated with
elevated susceptibility to, or worsening symptoms in response
to stress. A large scale longitudinal study showed an associa-
tion between inflammatory bowel disease (Crohn’s disease and
ulcerative colitis) and depressive symptoms (Ananthakrishnan
et al., 2013b). These disorders are strongly associated with per-
ceived life stress, with time to relapse predicted by stress levels
(Triantafillidis et al., 2013). Studies of metabolic syndrome, dia-
betes and associated cardiovascular diseases have shown that not
only is this suite of disorders associated with increased risk of
depression and a low-grade inflammatory state, but that chronic
stress is a strong promoting factor [reviewed in Kyrou and Tsigos
(2009)]. These interactions may have developmental antecedents,
with exposure to a high fat diet in early life being associated
with both altered HPA axis function, inflammatory regulation
and disordered behavioral profiles in later life (Sasaki et al.,
2013). Nonetheless, the question remains as to how these com-
plex systems interact in both the periphery and CNS, and by
what mechanisms these systems modulate neuronal function and
mood.
Synthetic glucocorticoids are used therapeutically at supra-
physiological levels for their anti-inflammatory effects. However,
when examining the relationship between the HPA axis and
the immune system in physiological or pathophysiological
states, the situation appears more complex. Glucocorticoids
modulate the immune system through binding to receptors
expressed by immune cells, which down-regulates transcrip-
tion of pro-inflammatory genes and up-regulates production
of anti-inflammatory cytokines (Barnes, 2006; Leonard, 2006).
Glucocorticoids also regulate the circulating numbers, tissue
distribution and activity profile of lymphocytes in a time-
dependent manner [comprehensively reviewed in Dhabhar
(2009)]. Compared to acute stress, chronic stress appears to sup-
press some of the protective aspects of immune regulation, whilst
enhancing the drive to a pro-inflammatory state. The complex-
ity of these interactions is reflective of the fact that chronic
stimulation of the HPA axis may not in fact result in a hyper-
cortisolaemic state; given the capacity of the HPA axis for neg-
ative feedback regulation, the baseline cortisol levels in chronic
stress may actually be lower than normal. Glucocorticoids can
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be used therapeutically as immuno-suppressants but in some
experimental models appear to have pro-inflammatory effects.
Part of this discrepancy may come from differences between
in vivo and in vitro models, however in addition the com-
plexities of chronic stress in an animal model should not be
overlooked. Chronic stress may appear to increase or decrease
circulating glucocorticoids depending on the method of stress
and the method of glucocorticoid measurement employed. An
animal with chronic down-regulation of HPA axis responsiv-
ity, for example, may respond to the acute stress of blood
collection or some forms of euthanasia with an overshoot of
normal glucocorticoid response, giving the impression of ele-
vated circulating hormone levels in response to the chronic
stress.
Immune activation may also feed back to modulate gluco-
corticoid sensitivity. Production of cytokines also up-regulates
expression of the GR and modulates the sensitivity of the
HPA axis to negative feedback (Arzt et al., 2000). Elevation of
pro-inflammatory cytokines, including IL-2, appears to inhibit
nuclear translocation of the GR and suppress glucocorticoid sig-
naling (Goleva et al., 2009; Schewitz et al., 2009). Likewise,
administration of IL-1 up-regulates HPA axis activity (Dunn,
2000). Systemic exposure to pro-inflammatory stimuli such as
bacterial LPS induces secretion of CRH, therefore activating the
HPA axis (Sternberg, 2006). These studies illustrate the com-
plex bidirectional interactions between HPA axis function and
regulation of inflammation. Potential sex-differences have been
suggested when assessing the effects of LPS on stress response.
Indeed, female rats showed a higher LPS-induced corticosterone
release compared to male animals (Tonelli et al., 2008). The rela-
tionship between HPA axis activity and inflammation may also
be regionally specific. The peripheral response to stress and HPA
activation is likely to be qualitatively, quantitatively and tempo-
rally distinct from that observed in the CNS. In a mouse model
of chronic stress, increases in basal inflammatory markers were
observed inmultiple brain regions (Barnum et al., 2012). Chronic
unpredictable stress can also up-regulate the response to periph-
eral inflammatory stimuli, mediated by glucocorticoid signaling
(Munhoz et al., 2006). This differs somewhat to the concept of
glucocorticoid signaling as immunosuppressive, and highlights
the need for further investigation of the nexus between HPA and
immune function in the brain. Microglia represents the critical
interface point between the activity of the HPA axis, circulat-
ing inflammatory signals and the brain’s inflammatory response.
Microglial number and morphological changes associated with
activation can be increased by chronic stress in animal mod-
els (Nair and Bonneau, 2006; Tynan et al., 2010). Blockade of
glucocorticoid signaling can block stress-induced sensitization
of microglial inflammatory responses (Frank et al., 2011), and
microglial activation can be primed by in vivo exposure to glu-
cocorticoids (Nair and Bonneau, 2006) or chronic stress (Farooq
et al., 2012). Within the CNS, the balance between pro- and
anti-inflammatory responses to peripheral immune stimuli is
modulated by the density of microglial cells (Pintado et al., 2011).
The relationship between microglial activation and the stress
response has been most comprehensively investigated in animal
models. Repeated exposure to restraint stress induced microglial
activation in male C57BL/6 mice, as measured by the degree
of proliferation of microglia (Nair and Bonneau, 2006). The
increase in microglial number was positively correlated with ele-
vation of serum corticosterone levels induced by stress exposure.
Similarly, chronic restraint stress caused a significant increase
in activated microglia and number of microglia in multiple
brain regions (Tynan et al., 2010; Hinwood et al., 2012), and
inescapable stress potentiates the microglial response to immune
stimuli (Frank et al., 2012). However, high doses of glucocorti-
coid agonists suppress the microglial production of inflammatory
cytokines (Chantong et al., 2012). These differential responses
may be reflective of central vs. peripheral differences, in addi-
tion to switching from a pro- to anti-inflammatory response
to physiological vs. pharmacological levels of glucocorticoids.
Nonetheless, the consensus from these studies is that microglia
are acutely sensitive to both HPA axis function and inflamma-
tory signals, and act as an inflection point between peripheral
and central responses to these stimuli. As discussed above, the
activation state of the microglial population has direct effects on
neuronal function, via secondary cytokine production, reactive
oxygen species production, neurotoxic effects and modulation of
neurotransmitter production.
CONCLUSIONS
It has long been established in traditional forms of medicine
and in anecdotal knowledge that the health of the body and
the mind are inextricably linked. Although strong associations
between somatic illnesses and psychiatric disturbances have rou-
tinely been described in the literature, it is only recently that
western medicine has sought to, or indeed had the means to,
investigate the mechanisms underlying these associations. Strong
and continually developing evidence now suggests that converg-
ing disruptions to inflammatory and endocrine pathways may
interact in both the periphery and the CNS to potentiate states
of psychiatric dysfunction, in particular depressed mood. Further
evidence highlights the potential role of the CNS inflammatory
FIGURE 1 | Biological mechanisms by which peripheral dysfunction
may impact on neuronal function and therefore psychiatric state.
Schematic illustration of the potential role of the CNS inflammatory cells,
microglia, as a critical nexus between HPA axis activity, inflammation, and
neuronal dysfunction.
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cells, microglia, as a critical nexus between HPA axis activity,
inflammation and neuronal dysfunction (Figure 1). Aspects of
these pathways may therefore present as possible targets for thera-
peutic interventions for psychiatric disease or psychiatric compli-
cations of somatic disease. Evenmore efficacious may be targeting
multiple aspects of these pathways or convergence points such as
central microglial cells.
In this review we have focused on the biological mechanisms
by which peripheral dysfunction may impact on neuronal func-
tion and therefore psychiatric state. However, we do not wish
to discount the psychological influence of ill health on men-
tal function. Clearly the psychological stresses associated with
chronic illness or suboptimal health may themselves potentiate,
perpetuate and exacerbate psychiatric disease. An effective clin-
ical approach to integrated patient management therefore may
need to target the HPA axis dysfunction, inflammatory changes or
other pathological processes associated with peripheral disorders,
but also approach the psychological health of the patient.
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